

# APP $\Delta$ C31 polyclonal antibody

Alzheimer's disease (AD) is a progressive neurodegenerative disease characterized by the senile plaques, neurofibrillary tangles and loss of synapses and neurons. AD has been largely viewed as a disease of toxicity being mediated by the accumulation of the amyloid beta ( $A\beta$ ) peptide as plaques within the brain resulting in damage to brain cells from the binding of damaging metals, reactive oxygen species production and direct damage to cellular membranes. Recent research has suggested that the  $A\beta$  peptide is a multifunctional peptide with non-pathological effects and that its association with AD is in conjunction with its roles in combination with other proteins such as the amyloid precursor protein (APP) resulting in the imbalance between the processes of memory formation and normal forgetting. It is through the interactions of the  $A\beta$  peptide with APP that the  $A\beta$  peptide itself can affect normal modulation and signaling of APP resulting in its indicated role in the pathogenesis of AD via signaling effects rather than chemical or physical effects. There are three major APP isoforms (APP695, APP751 and APP770) that are formed through alternative splicing of precursor mRNA. APP770 represents the canonical sequence. The APP695 isoform is preferentially expressed in the central nervous system, while APP770 and APP751 are more highly expressed in peripheral tissues. **It has been demonstrated that the full length APP695 can be cleaved via caspase at an intracellular site (Asp664) resulting in the release of a 31 amino acid C-terminal peptide (C31) from the remaining larger neo-APP fragment (APP  $\Delta$ C31) with both of these entities being pro-apoptotic.** Immunohistochemical analysis of human brain tissue demonstrated that this cytoplasmic cleavage occurs 4-fold greater in patients with AD versus normal patients and that these cleavage products are localized to plaques and tangles in key areas of the brain affected by the disease. A single genetic mutation of aspartic acid residue 664 to alanine of APP695 led to the complete blockage of the C-terminal cleavage *in vivo* reversing many characteristics of the AD phenotype in a transgenic mouse model. Additionally, in cell culture it has been suggested that the neurotoxicity of  $A\beta$  is dependent on the cleavage of APP at Asp664 and the resulting  $A\beta$ -facilitated APP multimerization.

This antibody is covered by our [Worry-Free Guarantee](#).

Citations: 2

[View Online »](#)


Ordering Information

Order Online »

ENZ-ABS445-0100	100µg
-----------------	-------

Manuals, SDS & CofA

View Online »



HEK cells were transfected with pCDNA3-APP695 (lane 2), pCDNA3-APP695 ΔC31 (lane 3) or pCDNA3 (lane 4) constructs. 10μg of total cell lysates were separated by 7.5% SDS-PAGE for Western Blot. The membrane was immunoblotted with primary antibody (ENZ-ABS445, APP ΔC31, pAb) at 1:1000 dilution. Anti-rabbit IgG-AP (Prod. No. ADI-SAB-301) was used at 1:4000 dilution. The result showed this antibody only detected APP695 ΔC31 at about 98 KDa. Pre-stained protein marker is shown in lane 1.

## Handling & Storage

**Handling** Avoid freeze/thaw cycles.

**Long Term Storage** -20°C

**Shipping** Blue Ice

**Regulatory Status** RUO - Research Use Only

## Product Details

**Alternative Name** Amyloid A4 protein C31 chain, ABPP, APPI

**Application** ELISA, IP, WB

**Formulation** Liquid. In PBS containing 0.09% sodium azide.

**Host** Rabbit

**Immunogen** Synthetic peptide corresponding to the sequence near the C-terminus of human APP.

**Purity Detail** Peptide affinity purified.

**Source** Purified from rabbit serum.

**Species Reactivity** Human, Mouse

**UniProt ID** P05067

**Worry-free Guarantee** This antibody is covered by our [Worry-Free Guarantee](#).



ENZO LIFE SCIENCES,  
INC.  
Phone: 800.942.0430  
[info-  
usa@enzolifesciences.com](mailto:info-usa@enzolifesciences.com)

European Sales Office  
ENZO LIFE SCIENCES  
(ELS) AG  
Phone: +41 61 926 8989  
[info-  
eu@enzolifesciences.com](mailto:info-eu@enzolifesciences.com)

Belgium, The Netherlands  
& Luxembourg  
Phone: +32 3 466 0420  
[info-  
be@enzolifesciences.com](mailto:info-be@enzolifesciences.com)

France  
Phone: +33 472 440 655  
[info-  
fr@enzolifesciences.com](mailto:info-fr@enzolifesciences.com)

Germany  
Phone: +49 7621 5500 526  
[info-  
de@enzolifesciences.com](mailto:info-de@enzolifesciences.com)

UK & Ireland  
Phone (UK customers):  
0845 601 1488  
Phone: +44 1392 825900  
[info-  
uk@enzolifesciences.com](mailto:info-uk@enzolifesciences.com)